Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 1;6(3):e149-e151.
doi: 10.1093/jpids/pix058.

Retrospective Analysis of Posaconazole Suspension Dosing Strategies in a Pediatric Oncology Population: Single-Center Experience

Sherry Mathew  1 , Michelle L Kussin  1 , Dazhi Liu  1 , Melissa Pozotrigo  1 , Brian Seyboth  1 , Jennifer Thackray  1 , Shirley Qiong Yan  1 , Meier Hsu  2 , Nina Cohen  1 , Susan K Seo  3
Affiliations

Retrospective Analysis of Posaconazole Suspension Dosing Strategies in a Pediatric Oncology Population: Single-Center Experience

Sherry Mathew et al. J Pediatric Infect Dis Soc. .

Abstract

Limited data on optimal posaconazole dosing strategies for pediatric patients exist. In this study, we found that the median initial dose in patients who achieved a posaconazole plasma concentration of 0.7 μg/mL was 22.8 mg/kg per day whereas the median initial dose in those who did not reach the target concentration was 15.8 mg/kg per day; this result suggests that higher initial doses might be warranted.

Keywords: oncology; pediatrics; posaconazole.

PubMed Disclaimer

References

    1. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335–47. - PubMed
    1. Döring M, Müller C, Johann PD et al. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis 2012; 12:263. - PMC - PubMed
    1. Bernardo VA, Cross SJ, Crews KR et al. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother 2013; 47:976–83. - PMC - PubMed
    1. Krishna G, Martinho M, Chandrasekar P et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007; 27:1627–36. - PubMed
    1. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2–12. - PubMed

LinkOut - more resources